BIBLIOGRAFIA

‘T HART BA, AMORS A. (2003) the use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system in Curr Opin Neurol, 16:375-383


BARKOFF F, FILIPPI M, MILLER DH, et al. (1997) Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis, in Brain, 120:2059-2069


CARTON H, et al (1998) Utilization and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium), in *J Neurol Neurosurg Psychiatry*, 64: 444-450


CHARCOT J.M. (1877) Lectures on the diseases of the nervous sistem, in New Sydenham Society, London


COCKERILL R, WARREN S. (1990) Care for caregivers: the needs of family members of MS patients, in J Rehabil, 56: 41-44

COELHO P. (1997) Manuale del guerriero della luce, asSaggi Bompiani, Milano


CONTI L. (1999) Repertorio delle scale di valutazione in psichiatria, Ed. SEE Firenze,


DESROSIER MB. (1992) Catanzaro M, Piller J. Living with chronic illness: social support and the well spouse perspective, in *Rehabilitation Nursing*, 17(2): 87-91

DEUTSCH F. (1975) Il misterioso salto dalla mente al corpo, Martinelli


FENICHEL O. (1951) Trattato di psicanalisi delle neurosi e delle psicosi, Astrolabio, Roma


FOLEY F.W., TRAUGOTT U. et al. (1992) A prospective study of depression and immune dysregulation in Multiple Sclerosis, in *Arch Neurol.*, 49: 238-244

GHEZZI A. (2004) Stress e sclerosi multipla, in *Contemporary Highlights in Multiple Sclerosis*, Elleboro Officina Libraria, Torino


technology assessment subcommittee of the american academy of neurology and the MS council for clinical practice guidelines, in Neurology, 58:169-178


HOMMES OR, WEINER HL. (2002) Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis, in Mult Scler, 8:139-141
JOHNSON KP, BROOKS BR, COHEN JA et al. (1998) Extended use of glatimer acetate (COPAXONE) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. *Neurology*, 50:701-708


MELE C., MULIERE E., RONCONE R., CASACCHIA M. (2000) Funzionamento sociale e interventi psicosociali integrati nella sclerosi multipla, Centro di Servizi Interdipartimentale Comportamenti Maladattivi, Clinica Psichiatrica, Università L’Aquila, POL.it


NOSEWORTHY JH, EBERS GC, VANDERVOORT MK, FARQUAR RE, YETISIR E, ROBERTS R. (1994) The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. in *Neurology*, 44:16-


PETTE H. (1942) Die akut entzündlichen erkrankungen des nervensystem, in *Thime Verlag Leipzing*, 385-387


PONTIGGIA G. (2000) Nati due volte, Mondadori


RUDICK RA, MILLER D, CLOUGH JD, GRAGG LA, FARMER RG. (1992) Quality of life in Multiple Sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis, in *Arc Neurol*; 49: 1237-1242


SCHILDER P. (1977) Immagine di Sé e schema corporeo, F. Angeli, Milano


SCHUMACHER GA. (1966) Multiple sclerosis, in *Arch Neurol*, 14:571-573

SEGAL H. (1968) L’introduzione all’opera di Melanie Klein, Martinelli

SEPULVEDA L. (1996) Storia di una gabbianella e del gatto che le insegnò a volare, Salani Editore, Milano


The PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) study group; and the University of British Columbia MS/MRI Analysis Group. PRISM-4: Long-term efficacy of interferon-β-1a in relapsing MS. 2001 *Neurology*;56:1628-1636.


SITOGRAFIA

www.aim.it
www.neuroingegneria.it
www.sclerosimultipla.gabama.com
www.neurologia.it
www.dica33.it
www.saluteuropa.it
www.lism.it
www.fondazioneserono.it
www.PubMed.com

http://periodici.caspur.it